Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9222)
All Articles published online
|
Publishing Process of This Article
|
Apr 28, 2015 (publication date) through Feb 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(16): 5072-5080 [PMID: 25945023 DOI: 10.3748/wjg.v21.i16.5072] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i16/5072.htm |
| Number | Citing Articles |
| 1 |
Álvaro Esteban Alfaro Alfaro, Brayan Murillo Castillo, Eugenia Cordero García, Javier Tascón, Ana I. Morales. Colon Cancer Pharmacogenetics: A Narrative Review. Pharmacy 2022; 10(4): 95 doi: 10.3390/pharmacy10040095
|
| 2 |
Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash, Emil Lou. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy - Oncolytics 2021; 22: 1 doi: 10.1016/j.omto.2021.05.001
|
| 3 |
Edina Tolnay, �ron Ghimessy, Erzs�bet Juh�sz, Zsuzsanna Sztancsik, Gy�rgy Losonczy, P�ter Dombi, Zsuzsanna Vennes, L�szl� Helf, Edit Csada, Veronika S�rosi. The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort study. Oncology Letters 2018; doi: 10.3892/ol.2018.9766
|
| 4 |
Jia Deng, Xinglin Zeng, Wenting Hu, Tinghui Yue, Zicheng Luo, Lian Zeng, Ping Li, Jiang Chen. Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis. International Journal of Colorectal Disease 2023; 38(1) doi: 10.1007/s00384-023-04442-5
|
| 5 |
Usman Ilyas, Zaryab Umar, Amee M Pansuriya, Abrahim Mahmood, Muhammad Haseeb ul Rasool, Zamaraq Bhatti. Rare Mucinous Adenocarcinoma of the Appendix Undergoing Multiple Recurrent Surgical Interventions. Cureus 2023; doi: 10.7759/cureus.33294
|
| 6 |
Selma YAMAN, Nursima ÇUKADAR, Furkan BARAN, Fatih Burak UYANIK, Metin KILINÇ, Tufan MERT. Monoklonal antikorlardan bevacizumab'ın deneysel inflamatuar ağrı modelinde antianjiyogenik etkisi. Cukurova Medical Journal 2019; 44: 33 doi: 10.17826/cumj.532813
|
| 7 |
Masahito Naito, Ryota Torii, Yuki Hashimoto, Yuki Kawamoto, Kenichi Hayashi, Hiroaki Shinoda, Yumiko Honjo, Motoki Hiroyoshi. Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer Patient. Chemotherapy 2019; 64(3): 163 doi: 10.1159/000503221
|
| 8 |
Elena M. Tosca, Maurizio Rocchetti, Enrico Pesenti, Paolo Magni. A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance. Cancer Research 2020; 80(4): 820 doi: 10.1158/0008-5472.CAN-19-0811
|
| 9 |
F.I. Mulder, N. van Es, N. Kraaijpoel, M. Di Nisio, M. Carrier, A. Duggal, M. Gaddh, D. Garcia, M.A. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, G. Royle, A. Segers, S. Shivakumar, P. Verhamme, T. Wang, J.I. Weitz, G. Zhang, H.R. Büller, G. Raskob. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thrombosis Research 2020; 185: 13 doi: 10.1016/j.thromres.2019.11.007
|
| 10 |
Tijl Vermassen, Karen Geboes, Marc De Man, Stéphanie Laurent, Elsie Decoene, Nicolaas Lumen, Joris Delanghe, Sylvie Rottey. Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents. Nephrology Dialysis Transplantation 2018; 33(3): 402 doi: 10.1093/ndt/gfx063
|
| 11 |
Erdem Bangi, Celina Ang, Peter Smibert, Andrew V. Uzilov, Alexander G. Teague, Yevgeniy Antipin, Rong Chen, Chana Hecht, Nelson Gruszczynski, Wesley J. Yon, Denis Malyshev, Denise Laspina, Isaiah Selkridge, Hope Rainey, Aye S. Moe, Chun Yee Lau, Patricia Taik, Eric Wilck, Aarti Bhardwaj, Max Sung, Sara Kim, Kendra Yum, Robert Sebra, Michael Donovan, Krzysztof Misiukiewicz, Eric E. Schadt, Marshall R. Posner, Ross L. Cagan. A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Science Advances 2019; 5(5) doi: 10.1126/sciadv.aav6528
|
| 12 |
Yuta Hara, Ryota Torii, Shiho Ueda, Erina Kurimoto, Eri Ueda, Hiroshi Okura, Yutaka Tatano, Hideki Yagi, Yoshiya Ohno, Toshiyuki Tanaka, Kazue Masuko, Takashi Masuko. Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1. Cancer Science 2018; 109(10): 3171 doi: 10.1111/cas.13755
|
| 13 |
Jae Hyun Kim, Seun Ja Park. Target Therapy in Unresectable or Metastatic Colorectal Cancer. The Korean Journal of Gastroenterology 2016; 68(6): 303 doi: 10.4166/kjg.2016.68.6.303
|
| 14 |
Hakan Kulacoglu, Ferdinand Köckerling. Hernia and Cancer: The Points Where the Roads Intersect. Frontiers in Surgery 2019; 6 doi: 10.3389/fsurg.2019.00019
|
| 15 |
Diana Cornelia Moisuc, Mihai Vasile Marinca, Bogdan Gafton, Teodora Alexa-Stratulat, Mariana Pavel-Tanasa, Petru Cianga. Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer. Current Oncology 2022; 29(6): 3996 doi: 10.3390/curroncol29060319
|
| 16 |
Naoya Toriu, Akinari Sekine, Hiroki Mizuno, Eiko Hasegawa, Masayuki Yamanouchi, Rikako Hiramatsu, Noriko Hayami, Junichi Hoshino, Masahiro Kawada, Tatsuya Suwabe, Keiichi Sumida, Naoki Sawa, Kenmei Takaichi, Kenichi Ohashi, Takeshi Fujii, Shuichiro Matoba, Yoshifumi Ubara. Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report. Case Reports in Oncology 2019; 12(2): 391 doi: 10.1159/000500716
|
| 17 |
Prashanth Rawla, Adam Barsouk, Andreas V. Hadjinicolaou, Alexander Barsouk. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Medical Sciences 2019; 7(8): 83 doi: 10.3390/medsci7080083
|
| 18 |
Li Ai, Chen Xin, Muhammad Usman, Yu Zhu, Hong Lu. Effect of Bevacizumab on traumatic penumbra brain edema in rats at different time points. Tissue Barriers 2024; 12(4) doi: 10.1080/21688370.2023.2292463
|
| 19 |
Philip Emmerich, Linda Clipson, Dustin A. Deming. Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications. Current Colorectal Cancer Reports 2017; 13(4): 334 doi: 10.1007/s11888-017-0374-5
|
| 20 |
Helga Hagman, Pär-Ola Bendahl, Jon Lidfeldt, Mattias Belting, Anders Johnsson, Aamir Ahmad. Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer. PLOS ONE 2018; 13(12): e0209838 doi: 10.1371/journal.pone.0209838
|
| 21 |
Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua, Ying Mao. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11043-6
|
| 22 |
Minjie Fu, Arshad Hussain, Youting Dong, Yang Fei. A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma. Journal of Clinical Neuroscience 2021; 86: 110 doi: 10.1016/j.jocn.2021.01.019
|
| 23 |
Tobias Engel Ayer Botrel, Luciana Gontijo de Oliveira Clark, Luciano Paladini, Otávio Augusto C. Clark. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2734-y
|
| 24 |
Chinese consensus on prevention of colorectal neoplasia (2021, Shanghai). Journal of Digestive Diseases 2022; 23(2): 58 doi: 10.1111/1751-2980.13079
|
| 25 |
N.A. Bhaskaran, L. Kumar. Treating colon cancers with a non-conventional yet strategic approach: An overview of various nanoparticulate systems. Journal of Controlled Release 2021; 336: 16 doi: 10.1016/j.jconrel.2021.06.008
|
| 26 |
Dengfeng Wang, Yang Yu, Pengxian Tao, Dan Wang, Yajing Chen, Hao Chen. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: protocol for a systematic review and meta-analysis. BMJ Open 2020; 10(1): e033267 doi: 10.1136/bmjopen-2019-033267
|
| 27 |
Susan A. Kennedy, Maria E. Morrissey, Margaret R. Dunne, Fiona O’Connell, Clare T. Butler, Mary-Clare Cathcart, Amy M. Buckley, Brian J. Mehigan, John O. Larkin, Paul McCormick, Breandán N. Kennedy, Jacintha O’Sullivan. Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07430-y
|
| 28 |
Pasquale F. Innominato, René Adam. Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit. Current Colorectal Cancer Reports 2016; 12(4): 208 doi: 10.1007/s11888-016-0326-5
|
| 29 |
Hasan Ahmad Albitar, Yahya Almodallal, Rick Nishimura, Vivek N. Iyer. Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 2020; 4(4): 460 doi: 10.1016/j.mayocpiqo.2020.01.002
|
| 30 |
Alok K. Mishra. Phagocytosis - Main Key of Immune System. Physiology 2023; 19 doi: 10.5772/intechopen.110619
|
| 31 |
Zipeng Lu, Maximilian Weniger, Kuirong Jiang, Stefan Boeck, Kai Zhang, Alexander Bazhin, Yi Miao, Jens Werner, Jan G. D’Haese. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Targeted Oncology 2018; 13(4): 447 doi: 10.1007/s11523-018-0578-x
|
| 32 |
Sabina Palma, Ariel O. Zwenger, María V. Croce, Martín C. Abba, Ezequiel Lacunza. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer 2016; 15(2): 104 doi: 10.1016/j.clcc.2015.11.001
|
| 33 |
M. Di Nisio, M. Candeloro, A.W.S. Rutjes, E. Porreca. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis 2018; 16(7): 1336 doi: 10.1111/jth.14149
|
| 34 |
Alexander Baraniskin, Barbara Buchberger, Christian Pox, Ulli Graeven, Julian W. Holch, Wolff Schmiegel, Volker Heinemann. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. European Journal of Cancer 2019; 106: 37 doi: 10.1016/j.ejca.2018.10.009
|
| 35 |
Minsu Lee, Jin-Young Choi, Joon Seok Lim, Mi-Suk Park, Myeong-Jin Kim, Honsoul Kim. Lack of anti-tumor activity by anti-VEGF treatments in hepatic hemangiomas. Angiogenesis 2016; 19(2): 147 doi: 10.1007/s10456-016-9494-9
|
| 36 |
Matthieu Siebert, Mohammad Alyami, Frederic Mercier, Colin Gallice, Laurent Villeneuve, Nathalie Laplace, Guillaume Passot, Naoual Bakrin, Olivier Glehen, Vahan Kepenekian. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study. European Journal of Surgical Oncology 2021; 47(1): 139 doi: 10.1016/j.ejso.2019.03.021
|
| 37 |
Jinhai Huang, Wenwen Wang, Jing Yu, Xinxin Yu, Qianqian Zheng, Fangli Peng, Zhifen He, Wenguang Zhao, Zhaoliang Zhang, Xingyi Li, Qinmei Wang. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model. Colloids and Surfaces B: Biointerfaces 2017; 159: 241 doi: 10.1016/j.colsurfb.2017.07.057
|
| 38 |
Wanjing Feng, Xiaodong Zhu. Efficacy prediction of targeted therapy for gastric cancer: The current status (Review). Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.9145
|
| 39 |
Ikhwan Rinaldi, Kevin Winston, Leroy David Vincent, Abdillah Wicaksono, Muhammad Prasetio Wardoyo, Yusuf Aji Samudera Nurrobi, Jessica Leoni. Overall Survival and Progression-Free Survival Comparison of Bevacizumab Plus Chemotherapy Combination Regiment versus Chemotherapy Only Regiment in Previously Untreated Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. Open Access Macedonian Journal of Medical Sciences 2022; 10(F): 269 doi: 10.3889/oamjms.2022.9375
|
| 40 |
Lidia Rita Corsini, Daniele Fanale, Francesco Passiglia, Lorena Incorvaia, Vincenzo Gennusa, Viviana Bazan, Antonio Russo. Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety 2018; 17(12): 1197 doi: 10.1080/14740338.2018.1550068
|
| 41 |
Cindy Neuzillet, Benoît Rousseau, Hemant Kocher, Philippe Bourget, Christophe Tournigand. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacology & Therapeutics 2017; 174: 145 doi: 10.1016/j.pharmthera.2017.02.028
|
| 42 |
Grigoris T. Gerotziafas, Ismail Elalamy. Risque thromboembolique en oncologie : réalités, actualités et perspectives. Bulletin du Cancer 2016; 103(9): 764 doi: 10.1016/j.bulcan.2016.07.001
|
| 43 |
Jinhu Li, Dongfang Wang, Fei Tang, Xinnan Ling, Wenjie Zhang, Zemin Zhang. Pan-cancer integrative analyses dissect the remodeling of endothelial cells in human cancers. National Science Review 2024; 11(9) doi: 10.1093/nsr/nwae231
|
| 44 |
Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, Lisa A. Gurski. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2021; 19(3): 329 doi: 10.6004/jnccn.2021.0012
|
| 45 |
Lee S. Rosen, Ira A. Jacobs, Ronald L. Burkes. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology 2017; 12(5): 599 doi: 10.1007/s11523-017-0518-1
|
| 46 |
Romain Chautard, Morgane Caulet, Olivier Bouché, Christophe Borg, Sylvain Manfredi, Olivier Capitain, Jean-Philippe Spano, William Raoul, Maxime Guéguinou, Olivier Herault, Aurélie Ferru, Cédric Pobel, Olivier Sire, Thierry Lecomte. Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer. Digestive and Liver Disease 2025; 57(1): 141 doi: 10.1016/j.dld.2024.07.022
|
| 47 |
Courtney S. Malo, Roman H. Khadka, Katayoun Ayasoufi, Fang Jin, Jackson E. AbouChehade, Michael J. Hansen, Raymond Iezzi, Kevin D. Pavelko, Aaron J. Johnson. Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00320
|
| 48 |
Giandomenico Roviello, Chiara Pacifico, Paola Corona, Daniele Generali. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis. Investigational New Drugs 2017; 35(4): 518 doi: 10.1007/s10637-017-0452-1
|
| 49 |
Christina E. Bailey, Alexander A. Parikh. Assessment of the risk of antiangiogenic agents before and after surgery. Cancer Treatment Reviews 2018; 68: 38 doi: 10.1016/j.ctrv.2018.05.002
|
| 50 |
Jorge Pablo Grondona. Extreme Hepatic Surgery and Other Strategies. 2017; : 79 doi: 10.1007/978-3-319-13896-1_6
|
| 51 |
David Arias Ron, Carmen M. Labandeira, Soledad Cameselle García, Jesús García Mata, Mercedes Salgado Fernández. Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report. Case Reports in Oncology 2020; 13(1): 69 doi: 10.1159/000505237
|
| 52 |
Marco Ravanelli, Giorgio Maria Agazzi, Elena Tononcelli, Elisa Roca, Paolo Cabassa, Gianluca Baiocchi, Alfredo Berruti, Roberto Maroldi, Davide Farina. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. La radiologia medica 2019; 124(9): 877 doi: 10.1007/s11547-019-01046-4
|
| 53 |
Luisa Seguella, Riccardo Capuano, Mirella Pesce, Giuseppe Annunziata, Marcella Pesce, Barbara de Conno, Giovanni Sarnelli, Laura Aurino, Giuseppe Esposito. S100B Protein Stimulates Proliferation and Angiogenic Mediators Release through RAGE/pAkt/mTOR Pathway in Human Colon Adenocarcinoma Caco-2 Cells. International Journal of Molecular Sciences 2019; 20(13): 3240 doi: 10.3390/ijms20133240
|
| 54 |
Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney, Claire M Vajdic. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. JNCI Cancer Spectrum 2020; 4(6) doi: 10.1093/jncics/pkaa076
|